Cargando…

Successful Treatment with Paclitaxel, Carboplatin, and Gemcitabine as Second-line Chemotherapy for Recurrent Urothelial Carcinoma of the Bladder with Glandular Differentiation After Radical Cystectomy: A Case Report

Urothelial carcinoma of the bladder (UCB) with glandular differentiation is a histological variant (HV) that is more likely to have positive extravesical tumors or nodes than those in pure UCB. Cisplatin-based neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) is more effective for pure...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukuhara, Hiroki, Kakizaki, Hiroshi, Kaneko, Hisashi, Yamanobe, Takuya, Ushijima, Masaki, Kuboki, Yuya, Tsuchiya, Norihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595231/ https://www.ncbi.nlm.nih.gov/pubmed/28932689 http://dx.doi.org/10.1016/j.eucr.2017.08.001

Ejemplares similares

Sequential Therapy with Gemcitabine and Carboplatin Followed by Paclitaxel as First Line Treatment for Advanced Urothelial Cancer
por: Kattan, Joseph G, et al.
Publicado: (2012)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022)

Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer
por: Koie, Takuya, et al.
Publicado: (2014)

Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus
por: Kurokawa, Masayuki, et al.
Publicado: (2020)

Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial.
por: Zielinski, C. C., et al.
Publicado: (1998)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
por: Yardley, D A, et al.
Publicado: (2018)

Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2013)

Effects of sequential paclitaxel–carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study
por: Wang, Fei, et al.
Publicado: (2016)

BCG instillation versus radical cystectomy for high-risk NMIBC with squamous/glandular histologic variants
por: Suh, Jungyo, et al.
Publicado: (2019)

Effect of third- and fourth-line systemic therapies for metastatic renal cell carcinoma
por: Naito, Sei, et al.
Publicado: (2019)

A pilot study of gemcitabine and paclitaxel as third-line chemotherapy in metastatic urothelial carcinoma
por: Naiki, Taku, et al.
Publicado: (2017)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

Randomized Phase II Study of First‐Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non‐Small Cell Lung Cancer: LOGIK0801
por: Takayama, Koichi, et al.
Publicado: (2020)

A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung
por: Yang, Jin-Ji, et al.
Publicado: (2014)

Use of Gemcitabine Plus Carboplatin Is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4–5
por: Kim, Hyung-Don, et al.
Publicado: (2021)

Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer
por: Harries, M, et al.
Publicado: (2004)

Survival Analysis and Clinical Outcomes between Paclitaxel and Carboplatin Versus Carboplatin and Gemcitabine in Patients with Advanced-stage Non-small-cell Lung Cancer: A Single-center Cohort Study
por: Boonsong, Thitaya, et al.
Publicado: (2022)

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
por: Yardley, Denise A., et al.
Publicado: (2015)

Ischemic Colitis Associated with Paclitaxel and Carboplatin Combination
por: Elsayed, Ahmed Gamal, et al.
Publicado: (2017)

Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy
por: Moschini, Marco, et al.
Publicado: (2017)

Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer
por: Miyata, Yasuyoshi, et al.
Publicado: (2015)

Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial
por: Huebner, G, et al.
Publicado: (2009)

Living kidney transplantation without perioperative anticoagulation therapy for a patient with heparin‐induced thrombocytopenia
por: Nishida, Hayato, et al.
Publicado: (2020)

The arguments for an early cystectomy in patients with urothelial carcinoma
por: Barski, Dimitri
Publicado: (2014)

Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
por: Yardley, Denise A., et al.
Publicado: (2016)

Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity
por: Helbekkmo, N, et al.
Publicado: (2007)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer
por: Barlow, C, et al.
Publicado: (2004)

Prognostic value of vascular mimicry in patients with urothelial carcinoma of the bladder after radical cystectomy
por: Zhou, Lin, et al.
Publicado: (2016)

Urethral Recurrence of Urothelial Carcinoma of the Bladder Following Radical Cystectomy: An Unusual Imaging Pattern
por: Özdemir, Meltem, et al.
Publicado: (2020)

The influence of serum sodium concentration on prognosis in patients with urothelial carcinoma treated by radical cystectomy
por: Zhang, Yan, et al.
Publicado: (2022)

Clinical relevance of seasonal changes in the prevalence of ureterolithiasis in the diagnosis of renal colic
por: Fukuhara, Hiroki, et al.
Publicado: (2016)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
por: Dessai, S. B., et al.
Publicado: (2016)

The association of four genetic variants with myelosuppression in gemcitabine‐treated Japanese is not evident in gemcitabine/carboplatin‐treated Swedes
por: Björn, Niclas, et al.
Publicado: (2022)

A Case of Urinary Bladder Urothelial Carcinoma with Squamous, Glandular, and Plasmacytoid Differentiation
por: Makise, Naohiro, et al.
Publicado: (2014)

Glandular differentiation in pT1 urothelial carcinoma of bladder predicts poor prognosis
por: Zhao, Guobin, et al.
Publicado: (2019)

Survival of Patients With UrAC and Primary BAC and Urothelial Carcinoma With Glandular Differentiation
por: Wang, Tao, et al.
Publicado: (2022)

Serum C-reactive protein level is a significant prognostic indicator in patients with advanced urothelial cancer treated with gemcitabine-cisplatin or carboplatin – preliminary results
por: Morizane, Shuichi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_79hjgtebujtikh6t85i028jneg